Denali Therapeutics (DNLI) Stock Forecast & Price Target

$20.92 +0.14 (+0.67%)

(As of 12/24/2024 04:20 PM ET)

Denali Therapeutics - Analysts' Recommendations and Stock Price Forecast (2025)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Rating

Moderate Buy

Based on 11 Analyst Ratings

Sell
0

Hold
2

Buy
9

Based on 11 Wall Street analysts who have issued ratings for Denali Therapeutics in the last 12 months, the stock has a consensus rating of "Moderate Buy." Out of the 11 analysts, 2 have given a hold rating, and 9 have given a buy rating for DNLI.

Consensus Price Target

$40.40
93.12% Upside

According to the 11 analysts' twelve-month price targets for Denali Therapeutics, the average price target is $40.40. The highest price target for DNLI is $90.00, while the lowest price target for DNLI is $26.00. The average price target represents a forecasted upside of 93.12% from the current price of $20.92.

Get the Latest News and Ratings for DNLI and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Denali Therapeutics and its competitors.

DNLI Analyst Ratings Over Time

Type	Current Forecast 12/27/23 to 12/26/24	1 Month Ago 11/27/23 to 11/26/24	3 Months Ago 9/28/23 to 9/27/24	1 Year Ago 12/27/22 to 12/27/23
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	9 Buy rating(s)	8 Buy rating(s)	8 Buy rating(s)	11 Buy rating(s)
Hold	2 Hold rating(s)	3 Hold rating(s)	1 Hold rating(s)	0 Hold rating(s)
Sell	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)	0 Sell rating(s)
Consensus Price Target	$40.40	$38.90	$38.33	$48.50
Forecasted Upside	93.12% Upside	57.62% Upside	30.25% Upside	118.37% Upside
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy	Buy

$19 for a FULL YEAR of stock picks?! (Ad)

We're offering you the chance to subscribe to Behind the Markets for an ENTIRE YEAR for just $19. But why? Because there is a very small window of time... as little as 25 days from now... That will change the market forever.

Click here to get in now>>>

DNLI Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

DNLI Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Denali Therapeutics Stock vs. The Competition

Type	Denali Therapeutics	Medical Companies	S&P 500
Consensus Rating Score	2.82	2.81	2.51
Consensus Rating	Moderate Buy	Moderate Buy	Moderate Buy
Predicted Upside	93.12% Upside	26,168.89% Upside	13.49% Upside
News Sentiment Rating	Positive News See Recent DNLI News	Positive News	Positive News

Recent Analyst Forecasts and Stock Ratings

Rating

Upside/Downside

Action

Time Frame

Start Date

End Date

Show

Export to Excel

Date	Brokerage	Analyst Name	Action	Rating	Price Target	Upside/Downside on Report Date
12/16/2024	Stifel Nicolaus 4 of 5 stars		Upgrade	Hold ➝ Buy	$37.00	+61.08%
11/7/2024	HC Wainwright 2 of 5 stars		Reiterated Rating	Buy ➝ Buy	$90.00 ➝ $90.00	+204.57%
11/1/2024	Jefferies Financial Group 2 of 5 stars		Boost Target	Buy ➝ Buy	$40.00 ➝ $45.00	+64.65%
10/11/2024	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Overweight ➝ Overweight	$29.00 ➝ $28.00	+6.99%
10/10/2024	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	D. Brill Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
10/7/2024	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	J. Schimmer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Overweight ➝ Neutral
Get the Latest News and Ratings for DNLI and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Denali Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
9/4/2024	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$25.00 ➝ $29.00	+15.45%
8/2/2024	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Buy ➝ Buy	$26.00 ➝ $32.00	+49.18%
8/2/2024	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform ➝ Outperform	$30.00 ➝ $26.00	+18.94%
4/9/2024	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$70.00 ➝ $32.00	+65.29%
2/29/2024	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Buy ➝ Buy	$73.00 ➝ $50.00	+142.01%
9/6/2023	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Buy	$38.00	+59.40%
4/12/2023	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating		Boost Target	Overweight	$61.00 ➝ $63.00	+164.26%
3/2/2023	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$85.00 ➝ $70.00	+156.41%
2/28/2023	Evercore ISI Subscribe to MarketBeat All Access for the recommendation accuracy rating		Lower Target	Outperform	$80.00 ➝ $50.00	+84.16%
1/30/2023	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	M. Goodman Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$50.00	+63.83%
1/30/2023	SVB Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating		Initiated Coverage	Outperform	$50.00	+58.88%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Thursday at 07:27 AM ET.

DNLI Forecast - Frequently Asked Questions

: According to the research reports of 11 Wall Street equities research analysts, the average twelve-month stock price forecast for Denali Therapeutics is $40.40, with a high forecast of $90.00 and a low forecast of $26.00.
: 11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Denali Therapeutics in the last year. There are currently 2 hold ratings and 9 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" DNLI shares.
: According to analysts, Denali Therapeutics's stock has a predicted upside of 93.12% based on their 12-month stock forecasts.
: Over the previous 90 days, Denali Therapeutics's stock had 1 upgrade and 1 downgrade by analysts.
: Denali Therapeutics has been rated by research analysts at Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group, JPMorgan Chase & Co., Raymond James, and Stifel Nicolaus in the past 90 days.
: Analysts like Denali Therapeutics more than other "medical" companies. The consensus rating score for Denali Therapeutics is 2.82 while the average consensus rating score for "medical" companies is 2.81. Learn more on how DNLI compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Ratings

Top Rated Stocks

More Ratings Tools

$19 for a FULL YEAR of stock picks?! (Ad)

Click here to get in now>>>

This page (NASDAQ:DNLI) was last updated on 12/26/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Denali Therapeutics (DNLI) Stock Forecast & Price Target